American Vietnamese Biotech (HSTC:AMV) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is American Vietnamese Biotech LT-Debt-to-Total-Asset?

American Vietnamese Biotech HSTC:AMV +9.09% LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. American Vietnamese Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

American Vietnamese Biotech's long-term debt to total assets ratio stayed the same from Mar. 2024 (0.00) to Mar. 2026 (0.00).

American Vietnamese Biotech  (HSTC:AMV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

American Vietnamese Biotech LT-Debt-to-Total-Asset Related Terms

American Vietnamese Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for American Vietnamese Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Vietnamese Biotech LT-Debt-to-Total-Asset Chart

American Vietnamese Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

American Vietnamese Biotech Quarterly Data
Jun17 Sep17 Dec17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

American Vietnamese Biotech LT-Debt-to-Total-Asset Calculation

American Vietnamese Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/1883202.465879
=0.00

American Vietnamese Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0/1942222.260483
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
American Vietnamese Biotech (HSTC:AMV) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on American Vietnamese Biotech and its competitors.
Is American Vietnamese Biotech's LT-Debt-to-Total-Asset too high?
American Vietnamese Biotech's current LT-Debt-to-Total-Asset is 0.00.
How does American Vietnamese Biotech's LT-Debt-to-Total-Asset compare to HSTC and STLT?
American Vietnamese Biotech's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on American Vietnamese Biotech and its competitors. American Vietnamese Biotech's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is American Vietnamese Biotech stock overvalued right now?
American Vietnamese Biotech (HSTC:AMV) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For American Vietnamese Biotech (HSTC:AMV), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

American Vietnamese Biotech Business Description

Address No. 85 Hoang Van Thai, 4th Floor, Phu Ma Duong Building, Tan Phu Ward, District 7, Ho Chi Minh, VNM
American Vietnamese Biotech Incorporation is a Vietnam-based pharmaceutical and biotechnology company. It trades pharmaceuticals and medical equipment, and produces and distributes vaccines, medical biological products, testing instruments, and chemicals. The company's portfolio includes rapid diagnostic test kits, notably for infectious diseases, as well as immunological and biological reagents used in clinical testing. It serves hospitals, clinics, diagnostic laboratories, and healthcare providers across Vietnam, with distribution through domestic medical supply channels and partnerships with international biotechnology firms. Revenue comes from the sale of its manufactured biological products and diagnostic tests, alongside trading margins on imported pharmaceuticals, medical devices, and laboratory chemicals. The company operates primarily in the Vietnamese healthcare market, where demand for local diagnostic and vaccine products supports its business.